Many companies believe that getting medical device approval in Japan might fast-track their entry into the U.S. market. This episode breaks down that misconception and reveals the strategic pathway that actually exists. We explore how the FDA’s Abbreviated 510(k) program allows manufacturers to leverage their existing PMDA data, focusing on the crucial role of internationally recognized consensus standards. Learn how this approach can save significant time and resources compared to a traditional submission, without compromising regulatory diligence. Key Questions: • Is there a direct reciprocity agreement between Japan's PMDA and the US FDA for device approvals? • How does an Abbreviated 510(k) submission differ from a Traditional one? • What are "recognized consensus standards," and why are they the key to this strategy? • Can I reuse testing data for biocompatibility and electrical safety from my Japanese submission for the FDA? • What is the Safety and Performance Based Pathway, and how is it related? • Does using the Abbreviated 510(k) program eliminate the need for a predicate device? • How can a declaration of conformity simplify the FDA review process? • What is the most important first step to leveraging a PMDA certification for FDA clearance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.